Outsourced Biopharma Production – New Analysis Showing You Revenue Forecasts What is the outlook for making biological active pharma ingredients (APIs) under contract? Visiongain’s new report predicts those revenues from 2015. There you see financial data, also assessing trends, technologies, clients’ needs and opportunities.
Our study gives you sales forecasts to 2025 at overall world market, submarket and national level. Discover what’s happening for those production services – outsourcing and off-shoring for biological drugs (biologics). That way you gain in knowledge, also helping your influence.
Please read on to explore that industry and see what future revenue it could generate.
Sales forecasts and discussions to help your research, analyses and decisions Our study shows you what the future holds for those pharma contract manufacturing organisations (CMOs). You see technological and commercial outlooks for producing medicinal components of biologics. And you discover trends to watch.
Besides revenue forecasting to 2025, our new work shows you recent results, growth rates and market shares. There you find original analysis, exploring trends and developments. You gain 57 tables, 49 charts and two interviews with biopharmaceutical companies.
Gains through analysing those drug-making services – advantages for your work Why miss information you need? Why struggle to find data? Instead let our analysis guide you through that outsourcing industry’s present and future. Your search has just become easier.
Discover where trends in that pharma service industry lead, exploring where the money lies, finding the most lucrative opportunities.
Although no study answers every question, the following sections show how our new investigation benefits your work.
Revenues for the world outsourced biological API market and submarkets What are the secrets of that industry’s progress? You explore the future of the overall world market for outsourcing that biopharma production.
First our report shows you individual revenue forecasting for three main submarkets to 2025, at world level, with discussions: • Mammalian cell cultures • Microbial fermentations (culturing) • Other biotechnological (expression) systems for yielding medical products.
For API revenues, our study breaks its overall world revenue forecast to 2025 into these five therapeutic classes: • Monoclonal antibodies (mAbs) • Insulin • Vaccines • Interferons • Human growth hormones.
That work explains what stimulates and restrains the biotech API industry, also showing you revenue trends and growth possible. You identify potentials and competition for companies providing those technologies and services to help pharmaceutical companies.
So avoid falling behind, missing business or losing influence. Instead discover how you can benefit by better understanding trends and opportunities from 2015 in that CMO industry.
Our study also gives you geographical revenue predictions for those services.
National markets – what outlooks for production needs and CMOs serving biopharma? You discover individual revenue forecasts to 2025 for 14 national markets: • United States (US) • Germany, France, UK, Italy, Spain (EU5 group) and Switzerland • Japan • Brazil, Russia, India and China (BRIC nations) • South Korea • Singapore.
For pharma service providers and their customers, many opportunities exist in developed and developing countries. Rising sales of novel biological drugs and biosimilars stimulate demands for outsourced producing of biologics.
There discover how you and your organisation can gain. You find needs and outlooks. Our work explains, also discussing issues affecting that outsourcing of bioproduction.
Developments, challenges and opportunities affecting producers of biological APIs Our study explains forces affecting that industry and market from 2015, including these influences: • Services in greatest demand for biopharma CMOs • Development and proliferation of cell lines and expression systems, including emerging technologies • Therapies in development (R&D) providing outsourcing opportunity for API makers • Challenges in making vaccines and other complex protein-based and recombinant medicines • Improving yields and efficiency in biopharmaceutical operations, including effects on downstream processing.
You also explore these aspects of the biologicals API market and industry: • Next-generation antibody development, including antibody-drug conjugates (ADCs) • Orphan drugs and personalised medicines – satisfying specialist production needs • Single-use bioreactors (disposable systems) for API manufacturers • Risks of overcapacity for biotechnological CMOs • Regulations (GMP and other standards) affecting that biopharmaceutical contracting.
There you investigate political, economic, social and technological questions, assessing outlooks for trade. You explore forces shaping that medical business, influencing its success.
Leading companies and 2019 market value – what success is possible? Our report predicts the world market for producing those therapeutic agents will reach $5.78bn in 2019, expanding fast from 2015 to 2025.
That analysis also shows you what organisations hold most potential. Companies our report profiles include these: • Boehringer Ingelheim BioXcellence • Celltrion • DSM Biologics • Lonza • Samsung BioLogics • FUJIFILM Diosynth Biotechnologies.
You also discover interviews with two companies in the industry – FUJIFILM Diosynth Biotechnologies and Avid Bioservices Inc. Hear what service providers do and think, helping you stay ahead and succeed.
Ways Biological Drug API Manufacturing Services: World Industry and Market Predictions 2015-2025 helps In these five main ways our investigation helps your work, benefiting your knowledge and influence: • Revenues to 2025 at world level, with forecasts for eight main submarkets – assess prospects for needs, demands, investments, marketing and sales • Forecasts to 2025 for 14 national markets in the Americas, Europe and Asia – investigate developed and developing countries for commercial potentials • Outlooks for established and rising contract service providers – explore competitors’ results, technology, capabilities, potentials and strategies • Interviews with companies – discover views to help you stay ahead in knowledge • Analysis of what stimulates and restrains the biological API market – assess challenges and strengths, helping you compete and gain advantages.
Information found nowhere else, helping your searches, analyses and decisions Our new report gives independent analysis. In it you gain competitive intelligence found only in that work. That way you investigate progress and possibilities for that industry, exploring what the future holds, gaining revenue predictions.
See in our survey how you could help your research, analyses, decisions, proposals and presentations. Also discover there how to save time and benefit your authority, helping your reputation for commercial insight on the biologics industry.
Trying our study now gives you market forecasting from 2015 – stay ahead for information Our new report shows you trends, opportunities and revenue forecasts to 2025 for contracted production of biopharmaceuticals. That analysis is for everyone examining biological drug making. So avoid missing out – please get our report here now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview
1.1 Contract Biotech API Manufacturing: World Market Review 2015
1.2 Benefits of this Report
1.2.1 How This Report Delivers
1.2.2 Main Questions Answered by This Analytical Report
1.3 Who is This Study For?
1.4 Methods of the Study
1.5 Frequently Asked Questions (FAQ)
1.6 Some Associated Reports
1.7 About Visiongain
2. Introduction to Biotech API Manufacturing Services
2.1 What are Biotech API Manufacturing Services?
2.1.1 Producing Biotech API: An Overview of the Manufacturing Process
2.1.2 Defining the Biotech API Manufacturing Market
2.1.3 Differing Expression Systems to Manufacture APIs
2.2 Challenges in Manufacturing Biotech API
2.3 Outsourcing: A Common Trend in Biotech API Manufacturing Services
2.4 Future Trends for the Biotech API Manufacturing Services Market
2.5 Glossary
3. Biotech API Manufacturing Services: World Market Outlook and Forecast 2015-2025
3.1 The Contract Biotech API Manufacturing Services Market Performance, 2014
3.1.1 Contract Biotech API Manufacturing Services: Forecast 2015-2025
3.2 Drivers and Restraints in the Biotech API Manufacturing Services Market
3.2.1 Important Drivers in the Biotech API Manufacturing Services Market for the Coming Decade
3.2.1.1 The Ageing Population is a Driver for Growth
3.2.1.2 The Patent Cliff Effect Will Stimulate Biologics and Biosimilar Development
3.2.1.3 Outsourcing as a Driver for Growth
3.2.1.4 Opportunities from the Long Pipeline Will Drive Growth
3.2.1.5 Increased Investment in Orphan Drugs from Companies
3.2.1.6 Emerging Markets Will Grow and Influence the Market
3.2.1.7 Technological Changes: Single-Use Technology Will Become Essential in the Next 10 Years
3.2.2 Restraints on Growth in the Biotech API Manufacturing Services Market
3.2.2.1 Pricing Pressures Will Limit Market Growth
3.2.2.2 Regulatory Restrictions Will Increase
3.2.2.3 Overcapacity Will Be Adverse to Market Growth for CMOs
3.2.2.4 Complexity of API Production is a Challenge
3.3 Outlook for the Outsourced Biotech API Services: Increased Demand
4. Biotech API Manufacturing Services Submarkets: World Market Outlook and Forecasts 2015-2025
4.1 Submarkets for the Biotech API Manufacturing Services Industry
4.1.1 The Mammalian Cell Culture Submarket
4.1.2 The Mammalian Cell Culture Submarket Forecast 2015-2025
4.1.3 ADCs and Next-Generation Antibodies Will Drive Growth 2015-2025
4.1.4 The Microbial Fermentation Submarket
4.1.5 The Microbial Fermentation Submarket Forecast 2015-2025
4.1.5.1 Increase in Demand for Insulin Will Drive Growth 2015-2025
4.1.6 Other APIs Expression Systems Are Still in Development
4.1.6.1 Plant-Made Pharmaceuticals
4.1.6.2 Yeast Cell Expression Systems
4.1.6.3 Insect Cell Expression Systems
4.1.6.4 Other Expression Systems Submarket Forecast 2015-2025
4.2 Chapter Summary: Positive Growth for the Market
5. Biotech API Manufacturing: Outlook for Leading Biological Drug Contract API Sectors, 2015-2025
5.1 Antibody Therapies: An Introduction to the Largest Contract API Biological Drug Sector
5.1.1 Contract API Monoclonal Antibody Manufacturing Forecast 2015-2025
5.1.2 Outlook: Outsourced Manufacturing for Monoclonal Antibody APIs Will Increase
5.2 Contract API Vaccine Manufacturing: A Promising Opportunity for CMOs
5.2.1 Contract API Vaccine Market: Outlook and Forecast 2015-2025
5.2.2 Challenges in Manufacturing Vaccines
5.3 Introduction to the Insulin Therapies Market and Outlook for the Contract API Insulin Therapies Market
5.3.1 Contract API Insulin Analogues Forecast 2015-2025
5.3.2 Insulin Analogues: In-House Production Restrains the Contract API Insulin Therapies Market Growth
5.3.3 Development Trends in the Contract API Insulin Market to 2025
5.4 Introduction to the Interferon Therapy Market and Outlook for the Contract API Interferon Therapy Market
5.4.1 Contract API Interferon Market Forecast 2015-2025
5.4.2 Unlikely to be Opportunities in the Contract API Interferon Market
5.5 Introduction to the Growth Hormone Market and Outlook for the Contract API Growth Hormone Manufacturing Market
5.5.1 Contract API Growth Hormone Market Forecast 2015 to 2025
5.5.2 Most Manufacturing is In-House for Growth Hormone Production
5.5.3 Long-Acting Therapies Provide Opportunity for Outsourcing
5.6 Chapter Summary: Outsourcing for Key Biological Products 2015-2025
6. Leading National Markets for Contract Biotech API Manufacturing Services, 2015-2025
6.1 Regional Breakdown of the World Biotech API Manufacturing Services Market
6.1.1 US and EU Dominate Growth for Leading National Submarkets 2015-2025
6.1.2 National Revenue Shares by 2025: Emerging Market Growth
6.2 Contract Biotech API Manufacturing in Europe 2015-2025
6.2.1 Strong Growth for the EU Revenue Forecasts 2015-2025
6.2.2 Forecasts for Switzerland and Leading EU National Revenues 2015-2025
6.2.2.1 Germany Leads the EU Biotech Market with Strong Growth
6.2.2.2 UK: Strong Research Sector Will Drive Market Growth
6.2.2.3 France: Strong Vaccine Development Industry
6.2.2.4 Switzerland: Headquarters for Leading Companies
6.2.2.5 Spain: Numerous Biotech Companies
6.2.2.6 Italy: Outlook and Forecast 2015-2025
6.2.3 US: A Market Leader in Biotech API Manufacturing
6.2.4 Japan: A Less Mature Contract Manufacturing Market
6.2.5 BRIC Market: Outlook and Forecasts for Emerging Markets 2015-2025
6.2.5.1 Emerging Nations May Develop a Presence in the Biologics Market
6.2.5.2 Increased Demand for Biosimilars and Biological Drugs 2015-2025
6.2.5.3 China is Poised for Growth: Forecast for 2015-2025
6.2.5.4 India Offers a Lower-Cost Advantage for Biotech API Manufacturing Services: Forecast 2015-2025
6.2.5.5 Brazilian and Russian Governments Promoting Domestic Biotech Development
6.2.5.6 Russian Biotech API Manufacturing Services Forecast: 2015-2025
6.2.5.7 Brazilian Biotech API Manufacturing Services Forecast: 2015-2025
6.2.6 South Korea: Market Forecast, 2015-2025
6.2.6.1 Leading CMOs Celltrion and Samsung BioLogics Drive the Market
6.2.7 Singapore: Market Forecast, 2015-2025
6.3 Summary of Chapter: Outlook for Leading National Submarkets, 2015-2025
7. Leading CMOs in the Biotech API Manufacturing Services Market, 2014
7.1 Four Companies Led the Market in 2014
7.2 Leading Companies by Capacity
7.2.1 Small-Scale Biopharmaceutical Manufacturing is a Common Trend
7.2.2 Barriers to Market Entry 2015-2025
7.2.2.1 The High Cost of Facilities: Acquisition as a Cheaper Alternative
7.3 FDA Opens Barriers for the Biosimilars Market
7.4 Boehringer Ingelheim BioXcellence
7.4.1 Strategic Outlook: Expanding into the Asian Market
7.5 Celltrion: Biologics Leader in Asia
7.5.1 Celltrion: Likely Target for Mergers and Acquisitions?
Figure 10.1 Contract Biotech API Manufacturing Market: Revenue Forecasts ($bn) by Sector, 2015, 2017, 2019, 2021, 2023 and 2025
Figure 10.2 Contract Biotech API Manufacturing Market: Revenue Forecasts ($bn) by Region, 2015, 2017, 2019, 2021, 2023 and 2025
3P Biopharmaceuticals
AbbVie
AbbVie Contract Manufacturing (part of AbbVie)
Adocia
Ajinomoto Omnichem
Ambrx
Amgen
Aptuit
arGEN-X N.V.
AstraZeneca
Avid Bioservices (part of Peregrine Pharmaceuticals)
Bachem
Banner Life Sciences (part of DPx Holdings)
BaroFold
Baxter International
Bayer
Biocad
Bioceuticals Arzneimittel (part of Stada)
Biocon
Biogen Idec
Bioplanta
Boehringer Ingelheim
Boehringer Ingelheim BioXcellence (part of Boehringer Ingelheim)
Bristol-Myers Squibb
Calico Life Sciences
Carbogen Amcis
Catalent
Celltrion
Cinfa
CMC Biologics
Cytovance Biologics
DPx Fine Chemicals (part of DPx Holdings)
DPx Holdings
DSM Biologics (was part of Royal DSM, now part of DPx Holdings)
DSM Sinochem Pharmaceuticals (part of DPx Holdings)
Eisai
Eli Lilly
EMD Millipore (part of Merck)
European Medicines Agency (EMA)
Ferring Pharmaceuticals
Food and Drug Administration (US FDA)
Fujifilm
FUJIFILM Diosynth Biotechnologies
Gallus Biopharmaceuticals (part of DPx Holdings)
GE Healthcare
Genentech (part of Roche)
Genmab
Genzyme (part of Sanofi)
Gilead Sciences
GlyTech
Granules
GSK
GSK Biopharmaceuticals (part of GSK)
Hexal (part of Novartis)
Hospira
Hospira One2One (part of Hospira)
Infinity Pharmaceuticals
International Diabetes Federation
Ipsen
Kalon Biotherapeutics (part of Fujifilm)
Korea Food and Drug Administration (KFDA)
Kyowa Hakko Kirin
Laureate Biopharma (part of DPx Holdings)
Lek Pharmaceuticals (Sandoz)
Lonza
Medice
Merck & Co.
Merck Biomanufacturing Network
Merck KGaA
Merck Millipore
Merck Serono
Millennium Pharmaceuticals
Millhouse LLC
Ministry for Food and Drug Safety [Korea]
Ministry of Health [Brazil]
Mitsubishi Gas Chemical Company
Mylan
Neopharm
Nikon
Norbitec
Nordmark Arzneimittel
Novartis
Novasep
Novo Nordisk
Nuron Biotech
Nycomed
Open Monoclonal Technology (OMT)
Opko Health
Patheon (part of DPx Holdings)
Patheon Biologics(part of DPx Holdings)
Peregrine Pharmaceuticals
Perrigo
Pfizer
Pharmacyclics
Pharmstandard
Phyton Biotech
Piramal Healthcare
Precision Biologics
Prolor Biotech
Quintiles
Recepta Biopharma
Redwood Bioscience (part of Catalent)
Relthy Laboratórios (part of Catalent)
Rentschler Biotechnologie
Roche
Royal DSM (part of DPx Holdings)
SAFC (part of Sigma-Aldrich)
Samsung
Samsung Bioepis (part of Samsung)
Samsung BioLogics (part of Samsung)
Sandoz (part of Novartis)
Sanofi
Schering-Plough (part of Merck & Co.)
SCM Pharma
Seattle Genetics
ShangPharma
SICOR Biotech (part of Teva)
Stada Arzneimittel
Sunshine Biopharma
Takeda
TAPI (part of Teva)
Teva Pharmaceutical Industries
Tonghua Dongbao Pharmaceutical
Toyobo Biologics
Tufts Center for the Study of Drug Development (CSDD)
Vertex
Vida Pharma
World Health Organization (WHO)
WuXi PharmaTech
Xcellerex
Zhangjiang Biotech and Pharmaceutical Base Development (ZJ Base)
Zhejiang Jiang Yuan Tang Biotechnology
Zhuhai United Laboratories
Download sample pages
Complete the form below to download your free sample pages for Biological Drug API Manufacturing Services: World Industry and Market Predictions 2015-2025
Download sample pages
Complete the form below to download your free sample pages for Biological Drug API Manufacturing Services: World Industry and Market Predictions 2015-2025
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Automation is a rising trend in the supply chain as a way to reduce time to market and enhance efficiency. Automation is appealing for a variety of reasons, the most important of which is that it reduces human contact and hence interference.
From a long-term perspective, the rapid growth of the mid-class economy will enhance the demand for OTC products in emerging economies such as China, India and Brazil.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
